These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12370475)

  • 1. Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient.
    Ihara M; Kohara N; Urano F; Ichinose H; Takao S; Nishida T; Saiki H; Kawamoto Y; Ikeda A; Takagi S; Shibasaki H
    Neurology; 2002 Oct; 59(7):1102-4. PubMed ID: 12370475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review].
    Asztalos Z; Egervári L; Andrássy G; Faludi G; Frecska E
    Neuropsychopharmacol Hung; 2014 Mar; 16(1):19-28. PubMed ID: 24687015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catatonia After Neuroleptic Malignant Syndrome Successfully Treated With Electroconvulsive Therapy.
    Che J; Muralidhara S; Egbert M; Sharma A
    Prim Care Companion CNS Disord; 2019 Aug; 21(4):. PubMed ID: 31424701
    [No Abstract]   [Full Text] [Related]  

  • 4. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome.
    Carroll BT; Taylor RE
    J Clin Psychopharmacol; 1997 Jun; 17(3):235-8. PubMed ID: 9169979
    [No Abstract]   [Full Text] [Related]  

  • 5. Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia.
    Komatsu T; Nomura T; Takami H; Sakamoto S; Mizuno K; Sekii H; Hatta K; Sugita M
    Intern Med; 2016; 55(19):2893-2897. PubMed ID: 27725556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome.
    Leuzzi V; Carducci C; Carducci C; Cardona F; Artiola C; Antonozzi I
    Neurology; 2002 Oct; 59(8):1241-3. PubMed ID: 12391354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel nonsense mutation of the GTP cyclohydrolase I gene in a family with dopa-responsive dystonia.
    Hong KM; Kim YS; Paik MK
    Hum Hered; 2001; 52(1):59-60. PubMed ID: 11359069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism.
    Hoenicka J; Vidal L; Godoy M; Ochoa JJ; García de Yébenes J
    Mov Disord; 2001 Mar; 16(2):364-6. PubMed ID: 11295799
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel mutation of the GTP-cyclohydrolase I gene in a patient with hereditary progressive dystonia/dopa-responsive dystonia.
    Imaiso Y; Taniwaki T; Yamada T; Yoshimura T; Hirano M; Ueno S; Kaneda N; Kira J
    Neurology; 1998 Feb; 50(2):517-9. PubMed ID: 9484387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel de novo point mutation in the GTP cyclohydrolase I gene in a Japanese patient with hereditary progressive and dopa responsive dystonia.
    Sasaki R; Naito Y; Kuzuhara S
    J Neurol Neurosurg Psychiatry; 1998 Dec; 65(6):947. PubMed ID: 9854983
    [No Abstract]   [Full Text] [Related]  

  • 11. Scoliosis in a dopa-responsive dystonia family with a mutation of the GTP cyclohydrolase I gene.
    Furukawa Y; Kish SJ; Lang AE
    Neurology; 2000 Jun; 54(11):2187. PubMed ID: 10851395
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome.
    Longhurst JG
    Br J Psychiatry; 1995 Apr; 166(4):537-8. PubMed ID: 7795930
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome and the catatonic dilemma.
    Caroff SN; Mann SC; Campbell EC
    Psychopharmacology (Berl); 2015 Feb; 232(3):661-2. PubMed ID: 25589146
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular biology examinations of dopa-responsive dystonia].
    Romstad A; Güttler F
    Ugeskr Laeger; 1999 May; 161(20):2960. PubMed ID: 10354785
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene.
    Furukawa Y; Guttman M; Sparagana SP; Trugman JM; Hyland K; Wyatt P; Lang AE; Rouleau GA; Shimadzu M; Kish SJ
    Ann Neurol; 2000 Apr; 47(4):517-20. PubMed ID: 10762165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopa responsive dystonia with Turner's syndrome: clinical, genetic, and neuropsychological studies in a family with a new mutation in the GTP-cyclohydrolase I gene.
    Nitschke M; Steinberger D; Heberlein I; Otto V; Müller U; Vieregge P
    J Neurol Neurosurg Psychiatry; 1998 Jun; 64(6):806-8. PubMed ID: 9647318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.
    Ghaziuddin N; Alkhouri I; Champine D; Quinlan P; Fluent T; Ghaziuddin M
    J ECT; 2002 Jun; 18(2):95-8. PubMed ID: 12195138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset.
    Hirano M; Tamaru Y; Ito H; Matsumoto S; Imai T; Ueno S
    Ann Neurol; 1996 Nov; 40(5):796-8. PubMed ID: 8957022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency?
    Hjermind LE; Johannsen LG; Blau N; Wevers RA; Lucking CB; Hertz JM; Friberg L; Regeur L; Nielsen JE; Sørensen SA
    Mov Disord; 2006 May; 21(5):679-82. PubMed ID: 16267845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome.
    Am J Psychiatry; 1989 Sep; 146(9):1240-2. PubMed ID: 2569842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.